litlas
ログインアカウント作成

Aleix Prat

2007–2025 年に発表

247
論文数
33,909
被引用数
93
h 指数
229
i10 指数

被引用数

Aleix Prat の年別被引用数1998 年: 被引用 1 件2003 年: 被引用 1 件2004 年: 被引用 1 件2007 年: 被引用 1 件2008 年: 被引用 1 件2009 年: 被引用 9 件2010 年: 被引用 25 件2011 年: 被引用 97 件2012 年: 被引用 187 件2013 年: 被引用 235 件2014 年: 被引用 306 件2015 年: 被引用 342 件2016 年: 被引用 325 件2017 年: 被引用 326 件2018 年: 被引用 330 件2019 年: 被引用 1,109 件2020 年: 被引用 1,451 件2021 年: 被引用 1,641 件2022 年: 被引用 1,530 件2023 年: 被引用 1,467 件2024 年: 被引用 2,354 件2025 年: 被引用 1,249 件2026 年: 被引用 31 件1999〜2002 年は被引用が無いため表示していません2005〜2006 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,856 件、この内訳の 23.4%中国: 引用元論文 2,233 件、この内訳の 13.6%イタリア: 引用元論文 1,090 件、この内訳の 6.6%イギリス: 引用元論文 895 件、この内訳の 5.4%スペイン: 引用元論文 780 件、この内訳の 4.8%ドイツ: 引用元論文 695 件、この内訳の 4.2%フランス: 引用元論文 632 件、この内訳の 3.9%カナダ: 引用元論文 495 件、この内訳の 3%オーストラリア: 引用元論文 409 件、この内訳の 2.5%日本: 引用元論文 374 件、この内訳の 2.3%ベルギー: 引用元論文 366 件、この内訳の 2.2%韓国: 引用元論文 352 件、この内訳の 2.1%
0%23.4%その他 26%

機関

分野

  • Medicine53.3%
  • Biochemistry, Genetics and Molecular Biology39.1%
  • Immunology and Microbiology2.7%
  • Computer Science1.3%
  • Engineering1%
  • Neuroscience0.6%
  • その他2%

トピック

  • HER2/EGFR in Cancer Research6.5%
  • Breast Cancer Treatment Studies6.5%
  • Advanced Breast Cancer Therapies5.3%
  • Cancer Immunotherapy and Biomarkers4.7%
  • Cancer Cells and Metastasis4.3%
  • Cancer Genomics and Diagnostics3.4%
  • その他69.3%

共著者

全論文

検索で開く
  1. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

    著者: Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron - New England Journal of Medicine 2022 被引用: 2,548

  2. Immune-related adverse events of checkpoint inhibitors

    著者: Manuel Ramos‐Casals, Julie R. Brahmer, Margaret K. Callahan, Alejandra Flores-Chávez, Niamh M. Keegan, Munther A. Khamashta, Olivier Lambotte, Xavier Mariette, Aleix Prat, María E. Suarez‐Almazor - Nature Reviews Disease Primers 2020 被引用: 1,388

  3. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    著者: Francesco Schettini, Núria Chic, Fara Brasó‐Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez‐Sáez, Bárbara Adamo, María Vidal, Esther Barnadas, Aranzazu Fernández-Martínez, Blanca González‐Farré, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Aňa Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat - npj Breast Cancer 2021 被引用: 691

  4. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

    著者: Harold J. Burstein, Giuseppe Curigliano, Beat Thürlimann, William P. Weber, Philip Poortmans, Meredith M. Regan, H.-J. Senn, Eric P. Winer, Michael Gnant, Stephan Aebi, Fabrice André, Carlos Barrios, Jonas Bergh, Hervé Bonnefoi, Denisse Bretel Morales, Sara Y. Brucker, Harold J. Burstein, David Cameron, Fátima Cardoso, Lisa A. Carey, Boon Chua, Eva Ciruelos, Marco Colleoni, Giuseppe Curigliano, Suzette Delaloge, Carsten Denkert, Peter Dubsky, Bent Ejlertsen, Florian Fitzal, Prudence A. Francis, Viviana Galimberti, Hebatallah Gamal El Din Mohamed Mahmoud, Judy E. Garber, Michael Gnant, William J. Gradishar, Bahadır M. Güllüoğlu, Nadia Harbeck, Chiun‐Sheng Huang, Jens Huober, André Ilbawi, Zefei Jiang, Steven Johnston, Eun Sook Lee, Sibylle Loibl, Monica Morrow, Ann H. Partridge, Martine Piccart, Philip Poortmans, Aleix Prat, Meredith M. Regan, Isabella Rubio, Hope S. Rugo, Emiel J. Rutgers, Felix Sedlmayer, Vladimir Semiglazov, Hans-Joerg Senn, Zhiming Shao, Tanja Španić, Petra Tesařová, Beat Thürlimann, Sergei Tjulandin, Masakazu Toi, Maureen Trudeau, Nicholas Turner, Inez Vaz Luis, Giuseppe Viale, Toru Watanabe, William P. Weber, Eric P. Winer, Binghe Xu - Annals of Oncology 2021 被引用: 803

  5. Clinical implications of the intrinsic molecular subtypes of breast cancer

    著者: Aleix Prat, Estela Pineda, Bárbara Adamo, Patricia Galván, Aranzazu Fernández-Martínez, Lydia Gaba, Marc Díez, Margarita Viladot, Ana Arance, Montserrat Muñoz-Mateu - The Breast 2015 被引用: 1,310

  6. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

    著者: Hope S. Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruíz‐Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas C. Turner, Nickolas A. Sophos, Juan Pablo Zarate, Christina Arce, Yu-Ming Shen, Stuart Turner, Hemanth Kanakamedala, Wei‐Chun Hsu, Stephen Chia - The Lancet Oncology 2021 被引用: 349

  7. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

    著者: Aleix Prat, Joel S. Parker, Olga Karginova, Cheng Fan, Chad Livasy, Jason I. Herschkowitz, Xiaping He, Charles M. Perou - Breast Cancer Research 2010 被引用: 2,135

  8. Frequency and spectrum of PIK3CA somatic mutations in breast cancer

    著者: Olga Martínez‐Sáez, Núria Chic, Tomás Pascual, Bárbara Adamo, María Vidal, Blanca González‐Farré, Esther Sanfeliu, Francesco Schettini, Benedetta Conte, Fara Brasó‐Maristany, A. Rodríguez, Débora Martínez, Patricia Galván, Ana Rodríguez, Antonio Martı́nez, Montserrat Muñoz-Mateu, Aleix Prat - Breast Cancer Research 2020 被引用: 376

  9. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

    著者: Sara M. Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Paré, Guillermo Villacampa, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Romualdo Barroso‐Sousa, Patricia Villagrasa, Michelle K. DeMeo, Molly DiLullo, Jorge Gómez Tejeda Zañudo, Jakob Weiß, Nikhil Wagle, Ann H. Partridge, Adrienne G. Waks, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Aleix Prat, Eric P. Winer - The Lancet Oncology 2023 被引用: 165

  10. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

    著者: Aleix Prat, Valentina Guarneri, Tomás Pascual, Fara Brasó‐Maristany, Esther Sanfeliu, Laia Paré, Francesco Schettini, Débora Martínez, Pedro Jares, Gaia Griguolo, Maria Vittoria Dieci, Javier Cortés, Antonio Llombart‐Cussac, Benedetta Conte, Mercedes Marín‐Aguilera, Núria Chic, Joan Anton Puig‐Butillé, Antonio Martı́nez, Patricia Galván, Yi‐Hsuan Tsai, Blanca González‐Farré, Áurea Mira, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, PierFranco Conte, Charles M. Perou - EBioMedicine 2022 被引用: 145

  11. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

    著者: Fátima Cardoso, Elżbieta Senkus, A. Costa, Efthymios Papadopoulos, Matti Aapro, Fabrice André, Nadia Harbeck, B. Aguilar Lopez, C.H. Barrios, Jonas Bergh, Laura Biganzoli, C.B. Boers-Doets, Maria João Cardoso, L.A. Carey, Javier Cortés, Giuseppe Curigliano, Véronique Dièras, Nagi S. El Saghir, Alexandru Eniu, Lesley Fallowfield, P.A. Francis, Karen A. Gelmon, S. Johnston, Bella Kaufman, Smruti Koppikar, I.E. Krop, Musa Mayer, Gertrude Nakigudde, B.V. Offersen, Shinji Ohno, Olivia Pagani, Shani Paluch–Shimon, Frédérique Penault‐Llorca, Aleix Prat, H.S. Rugo, G. W. Sledge, Danielle Spence, Christoph Thomssen, D.A. Vorobiof, B. Xu, Larry Norton, E.P. Winer - Annals of Oncology 2018 被引用: 1,190

  12. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

    著者: José Manuel Pérez-García, Géraldine Gebhart, Manuel Ruíz Borrego, Agostina Stradella, Begoña Bermejo, Peter Schmid, Frederik Marmé, Santiago Escrivá-de-Romaní, Lourdes Calvo, Nuria Ribelles, Noelia Martínez-Jáñez, Cinta Albacar, Aleix Prat, Florence Dalenc, Khaldoun Kerrou, Marco Colleoni, N. Afonso, Serena Di Cosimo, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Cortés, Antonio Llombart‐Cussac - The Lancet Oncology 2021 被引用: 160

  13. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

    著者: Aleix Prat, Alejandro Navarro, Laia Paré, Noemı́ Reguart, Patricia Galván, Tomás Pascual, Alex Martínez‐Martí, Paolo Nucíforo, Laura Comerma, Llúcia Alós, Núria Pardo, S. Cedrés, Cheng Fan, Joel S. Parker, Lydia Gaba, Iván Victoria, Núria Viñolas, Ana Vivancos, Ana Arance, Enriqueta Felip - Cancer Research 2017 被引用: 477

  14. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

    著者: Fátima Cardoso, Shani Paluch–Shimon, Eva Schumacher-Wulf, Leonor Vasconcelos de Matos, Karen A. Gelmon, Matti Aapro, Jyoti Bajpai, Carlos H. Barrios, Jonas Bergh, Elizabeth Bergsten-Nordström, Laura Biganzoli, Maria João Cardoso, Lisa A. Carey, Mariana Chávez‐MacGregor, Runcie C.W. Chidebe, Javier Cortés, Giuseppe Curigliano, Rebecca Dent, Nagi S. El Saghir, Alexandru Eniu, Lesley Fallowfield, Prudence A. Francis, Sandra X. Franco Millan, Jenny Gilchrist, Joseph Gligorov, William J. Gradishar, Renate Haidinger, Nadia Harbeck, Xichun Hu, Ranjit Kaur, Belinda E. Kiely, Sungbae Kim, Smruti Koppikar, Marion Kuper‐Hommel, Frédéric Lecouvet, Ginny Mason, Shirley Mertz, Volkmar Müller, Claire Myerson, Silvia P. Neciosup, Birgitte Vrou Offersen, Shinji Ohno, Olivia Pagani, Ann H. Partridge, Frédérique Penault‐Llorca, Aleix Prat, Hope S. Rugo, Elżbieta Senkus, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Daniel Vorobiof, Peter Vuylsteke, Theresa Wiseman, Binghe Xu, Alberto Costa, Larry Norton, Eric P. Winer - The Breast 2024 被引用: 197

  15. Deconstructing the molecular portraits of breast cancer

    著者: Aleix Prat, Charles M. Perou - Molecular Oncology 2010 被引用: 1,333

  16. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer

    著者: Deena M. A. Gendoo, Natchar Ratanasirigulchai, Markus S. Schröder, Laia Paré, Joel S. Parker, Aleix Prat, Benjamin Haibe-Kains - Bioinformatics, Bioinform. 2015 被引用: 410

  17. Dissecting the biological heterogeneity of HER2-positive breast cancer

    著者: Francesco Schettini, Aleix Prat - The Breast 2021 被引用: 133

  18. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

    著者: Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira, Fara Brasó‐Maristany, Nusaïbah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, María Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández‐Losa, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquı́n Arribas, Stefan Michiels, Alicia García‐Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nucíforo, Rodrigo Dienstmann, Chandra Verma, Núria López-Bigas, Maurizio Scaltriti, Mónica Arnedos, Cristina Saura, Violeta Serra - Nature Communications 2022 被引用: 120

  19. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    著者: Erica L. Mayer, Amylou C. Dueck, Miguel Martín, Gábor Rubovszky, Harold J. Burstein, M. Bellet-Ezquerra, Kathy D. Miller, Nicholas Zdenkowski, Eric P. Winer, Georg Pfeiler, Matthew P. Goetz, Manuel Ruíz‐Borrego, D. Mark Anderson, Zbigniew Nowecki, Sibylle Loibl, Stacy Moulder, Alistair Ring, Florian Fitzal, Tiffany A. Traina, Arlene Chan, Hope S. Rugo, Julie Lemieux, Fernando Henao, Alan P. Lyss, Silvia Antolín, Antonio C. Wolff, Marcus Vetter, Daniel Egle, Patrick G. Morris, Eleftherios P. Mamounas, Miguel Gil‐Gil, Aleix Prat, Hannes Fohler, Otto Metzger, Magdalena Schwarz, Carter DuFrane, Debora Fumagalli, Kathy Puyana Theall, Dongrui R. Lu, Cynthia Huang Bartlett, María Koehler, Christian Fesl, Angela DeMichele, Michael Gnant - The Lancet Oncology 2021 被引用: 255

  20. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

    著者: Antonio Llombart‐Cussac, Javier Cortés, Laia Paré, Patricia Galván, Begoña Bermejo, Noelia Martínez-Jáñez, María Vidal, Sònia Pernas, Rafael López‐López, Montserrat Muñoz-Mateu, Paolo Nucíforo, Serafín Morales, Mafalda Oliveira, Lorena de la Peña, Alexandra Peláez, Aleix Prat - The Lancet Oncology 2017 被引用: 341

  21. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

    著者: Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso‐Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquín Gavilá, Violeta Serra, Aleix Prat, Laia Paré, P. Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga, Ian E. Krop, David B. Solit, Gordon B. Mills, Lewis C. Cantley, Eric P. Winer, Nancy U. Lin, Jordi Rodón - Breast Cancer Research 2020 被引用: 146

  22. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

    著者: Aleix Prat, Cristina Saura, Tomás Pascual, Cristina Hernándo, Montserrat Muñoz-Mateu, Laia Paré, Blanca González‐Farré, Pedro L. Fernández, Patricia Galván, Núria Chic, Xavier González, Mafalda Oliveira, Miguel Gil‐Gil, Míriam Arumí, Neus Ferrer, Álvaro Montaño, Yann Izarzugaza, Antonio Llombart‐Cussac, Raquel Bratos, Santiago González Santiago, Eduardo Martínez de Dueñas, Sergio Hoyos, Beatriz Rojas, Juan Antonio Virizuela, Vanesa Ortega, Rafael López‐López, P. Céliz, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá - The Lancet Oncology 2019 被引用: 201

  23. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis

    著者: Chiara Molinelli, Flavia Jacobs, Elisa Agostinetto, Guilherme Nader Marta, Marcello Ceppi, Marco Bruzzone, Eva Blondeaux, Francesco Schettini, Aleix Prat, Giuseppe Viale, Lucia Del Mastro, Matteo Lambertini, Evandro de Azambuja - ESMO Open 2023 被引用: 75

  24. Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

    著者: Shunqiang Li, Dong Shen, Jieya Shao, Robert J. Crowder, Wenbin Liu, Aleix Prat, Xiaping He, Shuying Liu, Jeremy Hoog, Charles Lu, Li Ding, Obi L. Griffith, Christopher A. Miller, Dave Larson, Robert S. Fulton, Michelle Harrison, Tom Mooney, Joshua F. McMichael, Jingqin Luo, Tao Yu, Rodrigo Gonçalves, Christopher Schlosberg, Jeffrey Hiken, Laila Saied, César Sánchez, Therese Giuntoli, Caroline Bumb, Crystal Cooper, Robert T. Kitchens, Austin Lin, Chanpheng Phommaly, Sherri R. Davies, Jin Zhang, Megha Shyam Kavuri, Donna McEachern, Yi Dong, X. Cynthia, Timothy Pluard, Michael Naughton, Ron Bose, Rama Suresh, R. McDowell, Loren Michel, Rebecca Aft, William E. Gillanders, Katherine DeSchryver, Richard K. Wilson, Shaomeng Wang, Gordon B. Mills, Ana M. González-Angulo, John R. Edwards, Christopher A. Maher, Charles M. Perou, Elaine R. Mardis, Matthew J. Ellis - Cell Reports 2013 被引用: 625